메뉴 건너뛰기




Volumn 29, Issue 10, 2012, Pages 889-899

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers

Author keywords

BI 10773; Diabetes; Dipeptidyl peptidase 4 inhibitor; Drug drug interaction; Empagliflozin; Sitagliptin; Sodium glucose cotransporter 2 inhibitor

Indexed keywords

EMPAGLIFLOZIN; SITAGLIPTIN;

EID: 84872111344     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0055-3     Document Type: Article
Times cited : (55)

References (19)
  • 1
    • 0035146344 scopus 로고    scopus 로고
    • Renal gluconeogenesis: Its importance in human glucose homeostasis
    • Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001;24:382-91.
    • (2001) Diabetes Care , vol.24 , pp. 382-391
    • Gerich, J.E.1    Meyer, C.2    Woerle, H.J.3    Stumvoll, M.4
  • 2
    • 79651473537 scopus 로고    scopus 로고
    • Renal glucose reabsorption inhibitors to treat diabetes
    • Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32:63-71.
    • (2011) Trends Pharmacol Sci , vol.32 , pp. 63-71
    • Bailey, C.J.1
  • 3
    • 80054108953 scopus 로고    scopus 로고
    • Sodium-glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: A review of Phase II and III trials
    • Kipnes M. Sodium-glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials. Clin Investig. 2011;1:145-56.
    • (2011) Clin Investig , vol.1 , pp. 145-156
    • Kipnes, M.1
  • 4
    • 83655184724 scopus 로고    scopus 로고
    • Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors
    • Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83-90.
    • (2012) Diabetes Obes Metab , vol.14 , pp. 83-90
    • Grempler, R.1    Thomas, L.2    Eckhardt, M.3
  • 5
    • 77957608196 scopus 로고    scopus 로고
    • Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 10773, a sodium glucose cotransporter-2 (SGLT-2), in healthy volunteers
    • Port A, Macha S, Seman L, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 10773, a sodium glucose cotransporter-2 (SGLT-2), in healthy volunteers. Diabetes. 2010;59(Suppl. 1):A155.
    • (2010) Diabetes , vol.59 , Issue.SUPPL. 1
    • Port, A.1    MacHa, S.2    Seman, L.3
  • 6
    • 79952991707 scopus 로고    scopus 로고
    • Safety and tolerability of BI 10773, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, following 8-days treatment in patients with type 2 diabetes
    • Seman L, Macha S, Jones P, et al. Safety and tolerability of BI 10773, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, following 8-days treatment in patients with type 2 diabetes. Diabetes. 2010;59(Suppl. 1):A156.
    • (2010) Diabetes , vol.59 , Issue.SUPPL. 1
    • Seman, L.1    MacHa, S.2    Jones, P.3
  • 7
    • 19944427998 scopus 로고    scopus 로고
    • (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    • Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan- 2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48:141-51.
    • (2005) J Med Chem , vol.48 , pp. 141-151
    • Kim, D.1    Wang, L.2    Beconi, M.3
  • 8
    • 77957162913 scopus 로고    scopus 로고
    • Merck & Co, Inc. Whitehouse Station, NJ, USA
    • Januvia (sitagliptin) [package insert]. 2010; Merck & Co, Inc. Whitehouse Station, NJ, USA.
    • (2010) Januvia (Sitagliptin) [Package Insert]
  • 9
    • 58149090676 scopus 로고    scopus 로고
    • The role of incretins in glucose homeostasis and diabetes treatment
    • Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60:470-512.
    • (2008) Pharmacol Rev , vol.60 , pp. 470-512
    • Kim, W.1    Egan, J.M.2
  • 10
    • 32844473903 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers
    • Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28:55-72.
    • (2006) Clin Ther , vol.28 , pp. 55-72
    • Bergman, A.J.1    Stevens, C.2    Zhou, Y.3
  • 11
    • 28844482322 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
    • Herman GA, Stevens C, Van DK, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78:675-88.
    • (2005) Clin Pharmacol Ther , vol.78 , pp. 675-688
    • Herman, G.A.1    Stevens, C.2    Van, D.K.3
  • 12
    • 64349083605 scopus 로고    scopus 로고
    • Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006
    • Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122:443-53.
    • (2009) Am J Med , vol.122 , pp. 443-453
    • Cheung, B.M.1    Ong, K.L.2    Cherny, S.S.3    Sham, P.C.4    Tso, A.W.5    Lam, K.S.6
  • 13
    • 75549091263 scopus 로고    scopus 로고
    • Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control
    • Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-59.
    • (2009) Endocr Pract , vol.15 , pp. 540-559
    • Rodbard, H.W.1    Jellinger, P.S.2    Davidson, J.A.3    Einhorn, D.4    Garber, A.J.5    Grunberger, G.6
  • 14
    • 84867016516 scopus 로고    scopus 로고
    • 12th Ed. Chantilly VA: MedDRA Maintenance And Support Services Organization
    • MedDRA Introductory Guide. 12th ed. Chantilly, VA: MedDRA Maintenance and Support Services Organization; 2009.
    • (2009) MedDRA Introductory Guide
  • 15
    • 33947420172 scopus 로고    scopus 로고
    • Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes
    • Gallwitz B. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc). 2007;43:13-25.
    • (2007) Drugs Today (Barc) , vol.43 , pp. 13-25
    • Gallwitz, B.1
  • 16
    • 77958540127 scopus 로고    scopus 로고
    • Vildagliptin: A review of its use in type 2 diabetes mellitus
    • Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs. 2010;70:2089-112.
    • (2010) Drugs , vol.70 , pp. 2089-2112
    • Keating, G.M.1
  • 17
    • 80051654526 scopus 로고    scopus 로고
    • Saxagliptin: A clinical review in the treatment of type 2 diabetes mellitus
    • Kania DS, Gonzalvo JD, Weber ZA. Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus. Clin Ther. 2011;33:1005-22.
    • (2011) Clin Ther , vol.33 , pp. 1005-1022
    • Kania, D.S.1    Gonzalvo, J.D.2    Weber, Z.A.3
  • 18
    • 79953189076 scopus 로고    scopus 로고
    • Linagliptin: In type 2 diabetes mellitus
    • Scott LJ. Linagliptin: in type 2 diabetes mellitus. Drugs. 2011;71:611-24.
    • (2011) Drugs , vol.71 , pp. 611-624
    • Scott, L.J.1
  • 19
    • 81855192456 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of BI 10773, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, following co-administration in healthy volunteers
    • Friedrich C, Metzmann K, Rose P, Mattheus M, Pinnetti S, Woerle H-J. Pharmacokinetics and pharmacodynamics of BI 10773, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, following co-administration in healthy volunteers. Diabetes. 2011;60(Suppl. 1):A616-7.
    • (2011) Diabetes , vol.60 , Issue.SUPPL. 1
    • Friedrich, C.1    Metzmann, K.2    Rose, P.3    Mattheus, M.4    Pinnetti, S.5    Woerle, H.-J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.